SPRY Similar Chart Price Prediction
The price of SPRY is predicted to go up 8.33%, based on the high correlation periods with INLX. The similarity of these two price pattern on the periods is 98.33%.
SPRY
INLX
Up: 8.33%Similarity: 98.33%
SPRY Revenue Forecast
SPRY EPS Forecast
SPRY FAQs
What is SPRY revenue forecast for next quarter？
SPRY Analyst's Forecast
Louise Chen
Scotiabank
Buy
2025-03-07
Price Target
$30
Upside
+176.5%
Scotiabank analyst Louise Chen initiated coverage of ARS Pharmaceuticals with an Outperform rating and $30 price target. The firm says it is "time to take a look" at ARS shares "ahead of tailwinds that could drive robust uptake" of its newly launched neffy, a nasal spray alternative to epinephrine injections for severe allergic reactions. The share setup is good, with a product that addresses unmet needs, an experienced management team to launch it, and a price that is more affordable than generic epinephrine injections, the analyst tells investors in a research note.
Ryan Deschner
Raymond James
Strong Buy
2025-01-14
Price Target
$26 → $28
Upside
+133.14%
